Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 8/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625837 | 0.82 | TRPV1 (0.46) | LMNAIDO1KDRKDM4EMEN1 | |
| SCHEMBL5521825 | 0.82 | IDO1 (0.38) | LMNAIDO1KDRRAPGEF4KDM4E | |
| SCHEMBL1626104 | 0.82 | LMNA (0.35) | LMNAIDO1KDRRAPGEF4KDM4E | |
| SCHEMBL1625664 | 0.82 | LMNA (0.35) | LMNAIDO1KDRRAPGEF4KDM4E | |
| SCHEMBL1625527 | 0.82 | LMNA (0.35) | LMNAIDO1KDRRAPGEF4KDM4E | |
| SCHEMBL1627282 | 0.81 | IDO1 (0.38) | CNR2LMNAIDO1KDRRAPGEF4 | |
| SCHEMBL1625203 | 0.81 | MERTK (0.44) | ARLMNAMEN1ALDH1A1MAPT | |
| SCHEMBL6445478 | 0.78 | KDR (0.37) | LMNAADRB2KDRRAPGEF4KDM4E | |
| SCHEMBL1626693 | 0.78 | CA1 (0.40) | LMNAKDRMEN1ALDH1A1GAA | |
| SCHEMBL27582911 | 0.78 | MAPT (0.46) | LMNAKDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| CN-101967146-A | Ep4 receptor inhibitors to treat rheumatoid arthritis | PRIZER JAPAN INC | 2011-02-09 | — | — | CN | disclosed |
| CN-100579518-C | Use of EP4 receptor ligands for the manufacture of a medicament for the treatment of IL-6 related disorders | PFIZER | 2010-01-13 | — | — | CN | disclosed |
| CN-101023946-A | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER (US) | 2007-08-29 | — | — | CN | disclosed |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PFIZER INC. | 2007-03-22 | — | — | US | disclosed |
| US-7148234-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2006-12-12 | — | — | US | disclosed |
| CN-1658847-A | Use of EP4 receptor ligands for the treatment of IL-6 related disorders | PFIZER (US) | 2005-08-24 | — | — | CN | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| CN-1477960-A | EPA receptor inhibitors to treat rheumatoid arthritis | — | 2004-02-25 | — | — | CN | disclosed |
| CN-1476448-A | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ������ҩ������˾ | 2004-02-18 | — | — | CN | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | AR 1948/4885CNR2 133/4885LMNA 3018/4885 |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PTGER4, PTGER1, IL6 | AR 2109/4885CNR2 165/4885LMNA 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.